Eisai's Higher-Dosage Aricept Challenged By U.S. Consumer Group
This article was originally published in PharmAsia News
Executive Summary
Eisai's Aricept (donepezil) best-selling drug for treating Alzheimer's disease has come under attack by an American consumer group for lacking enough effectiveness to justify its side-effects